Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11742524 | 0.82 | TSHR (0.31) | TSHRHSD11B1 | |
| SCHEMBL1927992 | 0.77 | HSD11B1 (0.44) | TSHRHSD11B1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL21400807 | 0.76 | AKR1C4 (0.37) | — | |
| SCHEMBL6427735 | 0.74 | SLC6A12 (0.43) | HSD11B1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL14499819 | 0.74 | SLC6A12 (0.46) | TSHRBRD4SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL5639358 | 0.74 | SLC6A12 (0.46) | TSHRBRD4SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL5639352 | 0.74 | SLC6A12 (0.46) | TSHRBRD4SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL1863234 | 0.73 | — | — | |
| SCHEMBL16229100 | 0.73 | HSD11B1 (0.44) | TSHRHSD11B1 | |
| SCHEMBL11746880 | 0.72 | MEN1 (0.32) | TSHRBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237847-B1 | METHOD FOR THE STEREOSELECTIVE SYNTHESIS OF CYCLIC AMINO ACIDS | WARNER LAMBERT CO (US) | 2006-05-17 | — | — | EP | disclosed |
| US-6864390-B2 | Method for the stereoselective synthesis of cyclic amino acids | WARNER-LAMBERT COMPANY (US) | 2005-03-08 | — | — | US | disclosed |
| US-20030069438-A1 | Method for the stereoselective synthesis of cyclic amino acids | BRYANS JUSTIN STEPHEN (GB) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069438-A1 | Method for the stereoselective synthesis of cyclic amino acids | NPSR1, NTSR1, GAP43 | TSHR 2205/4885HSD11B1 1659/4885BRD4 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.